

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BROAD INTELLIGENCE INTERNATIONAL PHARMACEUTICAL HOLDINGS LIMITED

博智國際藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1149)

PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the English name of the Company from “Broad Intelligence International Pharmaceutical Holdings Limited” to “Anxin-China Holdings Limited” and the Chinese name of the Company from “博智國際藥業控股有限公司” to “中國安芯控股有限公司”.

A circular containing, among other matters, details of the proposed change of the Company name, together with a notice of EGM and the related proxy form, will be despatched to the Shareholders as soon as practicable.

PROPOSED CHANGE OF COMPANY NAME

The board of directors (the “**Board**”) of Broad Intelligence International Pharmaceutical Holdings Limited (the “**Company**”) proposes to change the English name of the Company from “Broad Intelligence International Pharmaceutical Holdings Limited” to “Anxin-China Holdings Limited” and the Chinese name of the Company from “博智國際藥業控股有限公司” to “中國安芯控股有限公司”, subject to the conditions set out below being fulfilled.

Reasons for the change of Company name

In October 2009, the Company and its subsidiaries (the “**Group**”) acquired Eagle Mascot Limited, which indirectly held 100% interest in 深圳市安芯數字發展有限公司 (Shenzhen An-xin Digital Development Co., Limited), an integrated solutions provider of high technology intelligent security warning systems (the “**Acquisition**”). In order to better reflect the Group’s business following the Acquisition, the Board proposes to change the Company’s name. In addition, the Board believes that the new name can improve the Company’s corporate image and identity, which the Board considers to be in the interests of the Company and the shareholders of the Company (the “**Shareholders**”) as a whole.

The proposed change of name of the Company will be subject to the following conditions:

- a. the passing of a special resolution by the Shareholders at an extraordinary general meeting of the Company (the “**EGM**”) to approve the change of the Company’s name; and
- b. the Registrar of Companies in the Cayman Islands approving the proposed change of the Company’s name.

The new name of the Company will take effect from the date of entry of the new name on the register maintained by the Registrar of Companies in the Cayman Islands. The Company will then carry out all necessary filing procedures with the Registrar of Companies in Hong Kong.

Effects of the change of the Company’s name

The proposed change of the name of the Company will not affect any rights of the Shareholders. All existing share certificates of the Company under the name of “Broad Intelligence International Pharmaceutical Holdings Limited” shall, after the proposed change of the Company’s name becoming effective, continue to be evidence of title to the ordinary shares of HK\$0.10 each in the share capital of the Company (the “**Shares**”) and will be valid for trading, settlement and delivery for the same number of Shares in the new name of the Company. As such, no arrangement will be made for the exchange of the existing share certificates of the Company for the new share certificates bearing the Company’s new name as a result of the change of the Company’s name.

Once the change of the Company's name has become effective, any new share certificates of the Company will be issued in the new name of the Company and the securities of the Company will be traded on The Stock Exchange of Hong Kong Limited in the new name.

GENERAL

An EGM will be convened and held for the Shareholders to consider and, if thought fit, approve the proposed change of the Company's name. A circular containing, among other things, details of the proposed change of the Company's name and a notice of EGM will be despatched to the Shareholders as soon as practicable. The Company will make further announcement to inform the Shareholders as to when the change of Company name and the stock short name of the Company (in both English and Chinese) become effective.

As no Shareholders have a material interest in the change of Company name, no Shareholders will be required to abstain from voting on the resolution to approve the change of the Company's name.

By Order of the Board
Broad Intelligence International Pharmaceutical Holdings Limited
Zhong Houtai
Chairman

Hong Kong, 21 June 2010

As at the date of this announcement, the Board comprises Mr. Zhong Houtai, Mr. Zhong Houyao, Mr. Lin Supeng and Mr. Yang Ma, all being the executive directors and Mr. Pei Renjiu, Mr. Li Kai Ming and Mr. Cheung Chuen, all being the independent non-executive directors.